These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 37630619)

  • 1. The Crosstalk between Gut Microbiota and Bile Acids Promotes the Development of Non-Alcoholic Fatty Liver Disease.
    Li Z; Yuan H; Chu H; Yang L
    Microorganisms; 2023 Aug; 11(8):. PubMed ID: 37630619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.
    Chen J; Thomsen M; Vitetta L
    J Cell Biochem; 2019 Mar; 120(3):2713-2720. PubMed ID: 30443932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Penthorum chinense Pursh. extract attenuates non-alcholic fatty liver disease by regulating gut microbiota and bile acid metabolism in mice.
    Li X; Zhao W; Xiao M; Yu L; Chen Q; Hu X; Zhao Y; Xiong L; Chen X; Wang X; Ba Y; Guo Q; Wu X
    J Ethnopharmacol; 2022 Aug; 294():115333. PubMed ID: 35500802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional changes of the gastric bypass microbiota reactivate thermogenic adipose tissue and systemic glucose control via intestinal FXR-TGR5 crosstalk in diet-induced obesity.
    Münzker J; Haase N; Till A; Sucher R; Haange SB; Nemetschke L; Gnad T; Jäger E; Chen J; Riede SJ; Chakaroun R; Massier L; Kovacs P; Ost M; Rolle-Kampczyk U; Jehmlich N; Weiner J; Heiker JT; Klöting N; Seeger G; Morawski M; Keitel V; Pfeifer A; von Bergen M; Heeren J; Krügel U; Fenske WK
    Microbiome; 2022 Jun; 10(1):96. PubMed ID: 35739571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caffeic acid phenethyl ester suppresses intestinal FXR signaling and ameliorates nonalcoholic fatty liver disease by inhibiting bacterial bile salt hydrolase activity.
    Zhong XC; Liu YM; Gao XX; Krausz KW; Niu B; Gonzalez FJ; Xie C
    Acta Pharmacol Sin; 2023 Jan; 44(1):145-156. PubMed ID: 35655096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphenol A induced hepatic steatosis by disturbing bile acid metabolism and FXR/TGR5 signaling pathways via remodeling the gut microbiota in CD-1 mice.
    Hong T; Zou J; He Y; Zhang H; Liu H; Mai H; Yang J; Cao Z; Chen X; Yao J; Feng D
    Sci Total Environ; 2023 Sep; 889():164307. PubMed ID: 37211107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Current Understanding of Bile Acids in Chronic Liver Disease.
    Farooqui N; Elhence A; Shalimar
    J Clin Exp Hepatol; 2022; 12(1):155-173. PubMed ID: 35068796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism.
    Pathak P; Xie C; Nichols RG; Ferrell JM; Boehme S; Krausz KW; Patterson AD; Gonzalez FJ; Chiang JYL
    Hepatology; 2018 Oct; 68(4):1574-1588. PubMed ID: 29486523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease.
    Wang C; Zhu C; Shao L; Ye J; Shen Y; Ren Y
    Mediators Inflamm; 2019; 2019():7659509. PubMed ID: 31341422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism.
    Wang S; Sheng F; Zou L; Xiao J; Li P
    J Adv Res; 2021 Dec; 34():109-122. PubMed ID: 35024184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Potential of Natural Plants Against Non-Alcoholic Fatty Liver Disease: Targeting the Interplay Between Gut Microbiota and Bile Acids.
    Sun Q; Xin X; An Z; Hu Y; Feng Q
    Front Cell Infect Microbiol; 2022; 12():854879. PubMed ID: 35356532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease-Associated Gut Microbiota Reduces the Profile of Secondary Bile Acids in Pediatric Nonalcoholic Fatty Liver Disease.
    Yu J; Zhang H; Chen L; Ruan Y; Chen Y; Liu Q
    Front Cell Infect Microbiol; 2021; 11():698852. PubMed ID: 34568090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Jiang-Tang-San-Huang pill alleviates type 2 diabetes mellitus through modulating the gut microbiota and bile acids metabolism.
    Tawulie D; Jin L; Shang X; Li Y; Sun L; Xie H; Zhao J; Liao J; Zhu Z; Cui H; Wen W
    Phytomedicine; 2023 May; 113():154733. PubMed ID: 36870307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crosstalk between bile acid-activated receptors and microbiome in entero-hepatic inflammation.
    Thibaut MM; Bindels LB
    Trends Mol Med; 2022 Mar; 28(3):223-236. PubMed ID: 35074252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota.
    Mori H; Svegliati Baroni G; Marzioni M; Di Nicola F; Santori P; Maroni L; Abenavoli L; Scarpellini E
    Metabolites; 2022 Jul; 12(7):. PubMed ID: 35888771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probiotics Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats via Gut Microbiota/FXR/FGF15 Signaling Pathway.
    Luo M; Yan J; Wu L; Wu J; Chen Z; Jiang J; Chen Z; He B
    J Immunol Res; 2021; 2021():2264737. PubMed ID: 34458376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications.
    Chen J; Vitetta L
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32717871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Farnesoid X Receptor Signaling Shapes the Gut Microbiota and Controls Hepatic Lipid Metabolism.
    Zhang L; Xie C; Nichols RG; Chan SH; Jiang C; Hao R; Smith PB; Cai J; Simons MN; Hatzakis E; Maranas CD; Gonzalez FJ; Patterson AD
    mSystems; 2016; 1(5):. PubMed ID: 27822554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism.
    Pathak P; Liu H; Boehme S; Xie C; Krausz KW; Gonzalez F; Chiang JYL
    J Biol Chem; 2017 Jun; 292(26):11055-11069. PubMed ID: 28478385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.
    Jiang C; Xie C; Li F; Zhang L; Nichols RG; Krausz KW; Cai J; Qi Y; Fang ZZ; Takahashi S; Tanaka N; Desai D; Amin SG; Albert I; Patterson AD; Gonzalez FJ
    J Clin Invest; 2015 Jan; 125(1):386-402. PubMed ID: 25500885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.